JMP Securities Downgrades Optimer Pharmaceuticals (OPTR) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Optimer Pharmaceuticals (OPTR) Posts Q2 Profit of $0.02/Sh
February 28, 2013 4:29 PM ESTOptimer Pharmaceuticals (NASDAQ: OPTR) reported Q4 EPS of $0.02, which may not compare to the estimate of ($0.38). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.05 million.
"2012 was an exciting year for Optimer. DIFICID is now available in over a... More
